Scientific feasibility	Hepatitis C examples
Epidemiologic susceptibility (e.g., no nonhuman reservoir, ease of spread, naturally induced immunity, ease of diagnosis)	There is no nonhuman reservoir, transmission occurs through human blood contact or through contaminated products that can be mitigated; sensitive and specific diagnostic tests are available.
Effective, practical intervention available (e.g., vaccine, curative treatment)	Curative treatment of high tolerability is available, achieving cure rates of >95%
Showed feasibility of elimination (e.g., documented elimination from an island or other geographic unit)	Micro-elimination programs such as has occurred in Iceland (an island) are being demonstrated (Scott et al. 2018a)

Political commitment	Hepatitis C examples
Perceived burden of the disease (e.g., extent, deaths, other effects; relevance to rich and poor countries)	Globally, viral hepatitis-related mortality now exceeds mortality of any other chronic infectious disease (GBD 2015 Mortality and Causes of Death Collaborators 2016; Stanaway et al. 2016)
Expected cost of eradication	Modeling conducted to date suggests that global implementation of hepatitis C elimination strategies (2018–2030) is cost effective and will become cost-saving by 2027 (Pedrana et al. 2018).
Synergy of eradication efforts with other interventions (e.g., potential for added benefits or savings)	Commitment to hepatitis C elimination will help progress toward Sustainable Development Goal 3 on health (Pedrana et al. 2018)
Need for eradication rather than control	Elimination is more cost-effective than control and leads to long-term benefits to the health system (Scott et al. 2017b; Pedrana et al. 2018)